Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

XmAb808

Bispecific antibody · Immune activation, directed at B7-H3 (CD276) and CD28 · developed by Xencor

Phase 1 Most advanced trial
XNCR Developer
2 Registered trials

What is XmAb808?

XmAb808 is a bispecific antibody that binds B7-H3 (CD276) on certain tumor cells and CD28 on cytotoxic T-lymphocytes. By engaging both, it activates and redirects T cells to B7-H3-expressing tumor cells. It is being studied in multiple solid tumors, including ovarian, head and neck, lung, breast, and colorectal cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Bispecific antibody
Targets
B7-H3 (CD276), CD28
Mechanism
Immune activation, directed at B7-H3 (CD276) and CD28
Pathways
T-cell activation, CTL-mediated tumor cell killing
Therapy area
Oncology
Developer
Xencor, Inc. (XNCR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07593092 Phase 1 Ovarian Cancer Recruiting XNCR
NCT05585034 Phase 1 Head and Neck Squamous Cell Carcinoma Completed XNCR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Ovarian CancerCastration-resistant Prostate CancerColorectal CancerHead and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamousOvarian Cancer, EpithelialRenal Cell Carcinoma, Clear CellTNBC - Triple-Negative Breast CancerUrothelial Carcinoma

Other drugs acting on CD276 / CD28

More from Xencor

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the XNCR page.

Follow XNCR, the company behind XmAb808

See XNCR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

XNCR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.